SAN DIEGO--(BUSINESS WIRE)--
Asante Solutions, Inc., manufacturer of the Asante Snap Insulin Pump,
and DexCom, Inc. (NASDAQ: DXCM) announced today their intention to
enable the Dexcom mobile app platform, which is currently under
development, to integrate and display insulin data from the Asante Snap
Insulin Pump. This will be the second insulin delivery device to be
integrated into the Dexcom mobile app, which is designed to aggregate
glucose and other diabetes-related data from patients’ devices and
display the integrated data on a smartphone. In June, Dexcom announced
its intention to maintain an “open architecture” approach to
diabetes-related data which will include an “Authorized by Dexcom” mark
to indicate the compatibility of devices and apps integrating Dexcom CGM
“Asante’s mission is to simplify the management of diabetes, both for
people with diabetes and their healthcare providers, and this is the
next step in doing so,” said David Thrower, CEO of Asante Solutions.
Integration with the Dexcom mobile platform is the next step in our
commitment to make pump data available where and how a patient will want
to view it,” Thrower continued.
“More than ever, we believe that effective diabetes management depends
on timely and accurate data. That is why we are excited to complete
development of our mobile app and integrate data from the Asante Snap™
Insulin Pump system,” said Kevin Sayer, Dexcom President and Chief
About Asante Solutions, Inc.
Based in the heart of Silicon Valley, Asante Solutions, Inc. is a
privately-held diabetes company. Asante was founded on a belief that
life could be made simpler for people with diabetes, and those who love
them. For more information, visit www.snappump.com.
About DexCom, Inc.
DexCom, Inc. (www.dexcom.com),
headquartered in San Diego, California, is developing and marketing
continuous glucose monitoring systems for ambulatory use by patients and
by healthcare providers in the hospital.
Dexcom Cautionary Statement Regarding Forward Looking Statements
Dexcom is a medical device company with a limited operating history.
Successful commercialization of the company’s products is subject to
numerous risks and uncertainties, including a lack of acceptance in the
marketplace by physicians and patients, the inability to manufacture
products in commercial quantities at an acceptable cost, possible delays
in the company’s development programs, the inability of patients to
receive reimbursement from third-party payors and inadequate financial
and other resources. Certain of these risks and uncertainties, in
addition to other risks, are more fully described in the company’s
quarterly report on Form 10-Q for the period ending June 30, 2014, as
filed with the Securities and Exchange Commission on August 6, 2014.
Steven R. Pacelli, 858-200-0200
President, Strategy and Corporate Development
Source: DexCom, Inc.